ASH 2024 - Shenzhen Neoimmune Co., Ltd's DLBCL MRD Research Findings Selected for the 66th ASH Annual Meeting

2024-12-05 15:57:11 neoimmune 54

The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7th to 10th, 2024, in San Diego, USA.Shenzhen Neoimmune Co., Ltd's multicenter clinical research project, the MeDIG Study, which features the largest sample size in China using ctDNA-IgNGS for MRD monitoring in DLBCL, has successfully been selected for presentation at the 2024 ASH Annual Meeting. The latest research progress will be unveiled through a poster display (Poster) on December 9th, 2024, from 6:00 PM to 8:00 PM. Stay tuned for this exciting update.


ASH 

The 66th American Society of Hematology (ASH 2024) Annual Meeting will take place from December 7-10, 2024, in San Diego, USA. The ASH Annual Meeting is a comprehensive international event in the field of hematology, covering both malignant and non-malignant hematological diseases, attracting over 25,000 hematologists and other healthcare professionals from more than 100 countries around the world each year.


图片关键词




Shenzhen Neoimmune Co., Ltd's ASH Submission


Submission ID: 204594


Category: Poster


Abstract Number: 4347


Title: Harnessing ctDNA to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study


Chinese Title: A Multicenter Clinical Study on DLBCL MRD Monitoring Using ctDNA-IgNGS


Collaborating Institutions: Institute of Hematology, Chinese Academy of Medical Sciences (CAMS), Shenzhen Neoimmune Co., Ltd, Shenzhen International Graduate School of Tsinghua University



图片关键词

(Poster Presentation Location and Time Information)


Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. The majority of DLBCL patients achieve remission after first-line treatment. However, up to 40% of patients experience disease recurrence, partly due to the persistent presence of measurable residual disease (MRD) at low levels, which is difficult to detect with standard imaging. Early identification of patients at high risk of recurrence during treatment can help develop risk-adapted therapies to improve survival. The MeDIG study is a multicenter prospective study aimed at evaluating the application value of MRD monitoring based on ctDNA and Ig gene sequencing in DLBCL patients.


The MeDIG study's interim results will be presented at this conference. The study enrolled over 100 patients, and the preliminary results demonstrate the high sensitivity and negative predictive value of IgNGS-MRD: The sensitivity of ctDNA detection in predicting the mid-treatment and end-of-treatment outcomes is as high as 100%, with negative predictive values of 95% and 100%, respectively, providing reliable efficacy predictions for patients.


For more details, please stay tuned for the 2024 ASH Annual Meeting.





Contact Us

8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.

TEL: 0755-8453-4802

EMAIL

query@neoimmune.cn